Leading Indicators, Wednesday December 3, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Wed Dec 3rd - #ARTL #DEVS #IMRN #LOT #WOK #VS #SONN #POLE #OMDA #IPWR #HCMA #CLNN #BWIN #ACHC #ADCT - More: crystalequityresearch.com/leading-indi... - #smallcap

Leading Indicators, Tuesday December 2, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Tue Dec 2nd - #BGLC #CDLR #ABTC #EPOW #BLTE #HKIT #DBVT #NIVF #DOGZ #RYOJ #FTEL #SDH #GIBO #WOK #JAGX #SONN #YKDG - More: crystalequityresearch.com/leading-indi... - #smallcap

Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc Sonnet BioTherapeutics (NASDAQ: SONN) announced that its stockholders approved the proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC at a special meeting held on Dec. 2, 2025.The company said the final voting results from the special meeting will be filed on a Form 8-K with the U.S. Securities and Exchange Commission.

#SONN Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc

www.stocktitan.net/news/SONN/sonnet-bio-the...

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting Sonnet BioTherapeutics (NASDAQ: SONN) adjourned its special meeting to allow additional time to solicit votes on the proposed business combination with Hyperliquid Strategies Inc (HSI) and Rorschach I LLC. Of the shares voted to date, more than 95% support the transaction. The board continues to recommend that stockholders vote FOR all proposals.The adjourned meeting will be held Dec 2, 2025 at 9:00 a.m. ET via https://web.viewproxy.com/sonn/2025SM; the record date is Oct 20, 2025. HSI shares have been approved for Nasdaq listing.

#SONN Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

www.stocktitan.net/news/SONN/sonnet-bio-the...

Newly formed Hyperliquid Strategies Inc. plans to raise $1 billion to purchase #HYPE tokens for its balance sheet.

Hyperliquid Strategies plans an IPO later this year.

#SONN

Sonnet Releases Virtual Investor "What This Means" Segment Sonnet BioTherapeutics (NASDAQ:SONN) has released a Virtual Investor segment featuring CMO Dr. Richard Kenney discussing updates on their SB221 clinical trial for platinum-resistant ovarian cancer (PROC). The company reported significant progress with two out of three patients showing partial responses in the E6 dose escalation cohort (1200 ng/kg).The company has completed enrollment for the expansion group at the highest maintenance dose and plans to add an E7 cohort with a 1500 ng/kg maintenance dose. A preliminary efficacy readout is expected later this year, with plans to proceed to a randomized Phase 2a study in 2026, comparing the treatment to standard of care.

#SONN Sonnet Releases Virtual Investor "What This Means" Segment

www.stocktitan.net/news/SONN/sonnet-release...

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer Sonnet BioTherapeutics (NASDAQ:SONN) announced the expansion of its clinical study evaluating SON-1010 in combination with atezolizumab for platinum-resistant ovarian cancer (PROC). The company reported promising results, with 2 out of 3 patients (66%) achieving partial response at the E6 dose level (1200 ng/kg).Following these positive outcomes, Sonnet is adding a new E7 cohort to test a 25% higher maintenance dose (1500 ng/kg) before proceeding to the randomized Phase 2a portion. The combination therapy has shown acceptable safety signals and controlled induction of IFN. The company expects top-line readouts in Q4 2025.Previously, in the SB101 monotherapy trial, SON-1010 demonstrated an 83% clinical benefit rate (5 of 6 patients) at the 1200 ng/kg dose.

#SONN Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

www.stocktitan.net/news/SONN/sonnet-bio-the...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Mon Jul 14th - #EDHL #UMAC #DARE #PROK #ABVE #BMGL #HIVE #ONDS #YHC #SONN #RIG #SQFT #UMAC #WULF #AIFF #TDOC #SBET #RCAT #EOSE #BMNR #SRFM - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Breaking News: ( NASDAQ: #SONN ) Merger Madness Bastille Day 2025: From Biotech to Blockchain, AI Gaming, and Bots-Wall Street's Wild New Frontier

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy Sonnet BioTherapeutics (NASDAQ: SONN) has announced a transformative $888 million business combination with Rorschach I LLC to create Hyperliquid Strategies Inc (HSI), which will become the largest U.S.-based public company holding HYPE cryptocurrency in its treasury.The deal includes $583 million in HYPE tokens (12.6 million tokens) and $305 million in gross cash. Notable strategic investors include Paradigm, Galaxy Digital, Pantera Capital, and others. Post-merger, Bob Diamond will serve as Chairman and David Schamis as CEO of HSI.The transaction includes a $5.5 million private placement and conversion of $2.0 million in convertible notes. Current Rorschach owners and new investors will own approximately 98.8% of HSI, while SONN legacy stockholders will retain 1.2%. The deal is expected to close in H2 2025.

#SONN Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

www.stocktitan.net/news/SONN/sonnet-bio-the...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Wed Jul 2nd - #RXRX #SBET #DAIC #BTBT #WULF #WGHTQ #VLRS #BB #RUN #SONN #QUBT #LEU #HUT #EYEN #ESPR #CLSK #CERS #BMNR #BBAI #APLD - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Wednesday's Top 6 Momentum Stocks Gainers < $10.00 (July 02, 2025) are: $SONN $4.15 (223%), $MOGO $2.57 (97%), $ELWS $3.17 (82%), $DAIC $8.19 (64%), $NAMM $10.96 (61%), $LIXT $2.02 (61%) #SONN #swingtrading #investing #stocktrading

Join me in wishing this fucking stud a happy birthday!!

Who wants in on his birthday shenanigans?

✊🏻💦JFF: justfor.fans/CannaCruisers
✊🏻💦OF: onlyfans.com/reddandsonn

#sonn #birthdayboy #gaycouple #AlphaMuscle #dadandson #dadandboy #bears #beardedgay #masculinegay

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Wed Jun 18th - #TMC #RELI #PRTH #OMEX #MRIN #LGHL #HSDT #GALT #FLL #ZENV #SONN #CCLD #BDRX #APVO #RHC #MTR #NINE #HUYA #GHLD #WHLR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

a black and white poster with the words if not now when ALT: a black and white poster with the words if not now when

#SONN

SAVE OUR NATION NOW

Clinical Trial Success: Sonnet's Cancer Drug SON-1010 Achieves Critical Safety Goals Management discusses promising safety results for SON-1010 cancer therapy in Phase 1b/2a trial. Breakthrough potential for solid tumors and ovarian cancer. Full analysis inside.

#SONN Sonnet Releases Virtual Investor "What This Means" Segment

www.stocktitan.net/news/SONN/sonnet-release...

Latest Immunotherapy Developments Revealed in Sonnet BioTherapeutics Strategic Update New video details Sonnet's progress in immunotherapy drug development for tumor microenvironment. Access key insights and strategic direction. Full analysis inside.

#SONN Sonnet Announces Release of Corporate Update Video

www.stocktitan.net/news/SONN/sonnet-announc...

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas Sonnet BioTherapeutics (NASDAQ:SONN) announced positive findings from the first safety review of SON-1010 in combination with trabectedin for advanced leiomyosarcoma and liposarcoma treatment. The Safety Review Committee found no unexpected toxicities in the first 7 patients at the maximum tolerated dose (MTD) of 1200 ng/kg.Key findings include:6 out of 7 patients are tolerating the combination treatment after two months83% of patients in the high-dose monotherapy group showed stable disease at 4 monthsClinical benefit observed in 54% of patients during SON-1010 dose escalationAdverse events were mild to moderate, including fatigue, fever, chills, and myalgiaThe expansion cohort aims to enroll up to 18 patients, targeting a potential $2.1B global market opportunity in the trabectedin space. The study evaluates SON-1010, a proprietary version of IL-12, combined with trabectedin for improved treatment outcomes in soft tissue sarcomas.

#SONN Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

www.stocktitan.net/news/SONN/sonnet-bio-the...

Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 Exclusive insights from CEO Pankaj Mohan showcases Sonnet's immunotherapy pipeline and strategic vision. On-demand presentation reveals key growth drivers for investors.

#SONN Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

www.stocktitan.net/news/SONN/sonnet-bio-the...

Revolutionary Cancer Treatment Breakthrough: Sonnet's IL-12 Protein Research Heads to AACR 2025 Sonnet BioTherapeutics to showcase groundbreaking albumin-binding IL-12 fusion protein research for cancer immunotherapy at AACR IO 2025 Conference

#SONN Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

www.stocktitan.net/news/SONN/sonnet-bio-the...